Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
The bromodomain and extra-terminal (BET) bromodomains, particularly BRD4, have been identified as promising therapeutic targets in the treatment of many human disorders such as cancer, inflammation, obesity, and cardiovascular disease. Recently, the discovery of novel BRD4 inhibitors has garnered su...
Main Authors: | Zhimin Zhang, Lili Gu, Beibei Wang, Wenhai Huang, Yanmin Zhang, Zhen Ma, Shenxin Zeng, Zhengrong Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2019.1587417 |
Similar Items
-
Targeting BRD9 for Cancer Treatment: A New Strategy
by: Zhu X, et al.
Published: (2020-12-01) -
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Adam P. Cribbs, et al.
Published: (2021-02-01) -
Targeting mechanotransduction at the transcriptional level: YAP and BRD4 are novel therapeutic targets for the reversal of liver fibrosis
by: Altynbek Zhubanchaliyev, et al.
Published: (2016-12-01) -
BRD4: An emerging prospective therapeutic target in glioma
by: Hua Yang, et al.
Published: (2021-06-01) -
A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression
by: Zijun Zhou, et al.
Published: (2020-07-01)